147283-96-3

Upstream product

• 18282-51-4 4-iodo-benzyl alcohol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 619-58-9 4-iodobenzoic acid 
• 106-37-6 1.4-dibromobenzene 
• 288-32-4 1H-imidazole 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 1711-02-0 4-iodobenzoic acid chloride 
• 15290-29-6 4-(trimethylsilyl)benzoic acid 
• 6999-03-7 1-bromo-4-(trimethylsilyl)benzene 

Downstream Products

• 157756-27-9 5-<4'-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl><1,1'-biphenyl>-2-yl>-2-(triphenylmethyl)-1H-tetrazole 
• 870646-13-2 [4-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-(4-iodo-phenyl)-methanol 
• 909124-87-4 [3-(3-bromo-propoxy)-4-(1-hydroxy-ethyl)-phenyl]-[4-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-methanone 
• 137314-06-8 4-allyloxy-1-[(tert-butyl(dimethyl)silyloxy)methyl]benzene 
• 870646-24-5 4-(4-iodo-benzoyl)-benzaldehyde 
• 870646-23-4 (4-hydroxymethyl-phenyl)-(4-iodo-phenyl)-methanone 
• 870646-15-4 C₁₄H₉⁽³⁾HO₃ 
• 870646-14-3 4-(4-iodobenzoyl)benzoic acid 
• 870646-25-6 C₇₁H₁₁₉⁽³⁾HO₁₀Si₄ 
• 150438-02-1 CI 996 
• 143722-28-5 5-(4'-Methanesulfonyloxymethyl-1,1'-biphenyl-2-yl)-2-triphenylmethyl-2H-tetrazole 
• 1027968-99-5 2-Propyl-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5-[2-(2,2,2-trifluoro-acetyl)-pyrrol-1-yl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 1026262-77-0 2-Propyl-5-[2-(2,2,2-trifluoro-acetyl)-pyrrol-1-yl]-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 147283-97-4 dimethyl 4-(tert-butyldimethylsiloxymethyl)phenylphosphonate 

Relevant academic research and scientific papers

New inha inhibitors based on expanded triclosan and di-triclosan analogues to develop a new treatment for tuberculosis

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely contributed to clinical isoniazid resistance. We aimed to design new ‘direct’ InhA inhibitors that obviate the need for activation by KatG, circumventing pre-existing resistance. In silico molecular modelling was used as part of a rational structure-based drug-design approach involving inspection of protein crystal structures of InhA:inhibitor complexes, including the broad spectrum antibiotic triclosan (TCS). One crystal structure exhibited the unusual presence of two triclosan molecules within the Mycobacterium tuberculosis InhA binding site. This became the basis of a strategy for the synthesis of novel inhibitors. A series of new, flexible ligands were designed and synthesised, expanding on the triclosan structure. Low Minimum Inhibitory Concentrations (MICs) were obtained for benzylphenyl compounds (12, 43 and 44) and di-triclosan derivative (39), against Mycobacterium bovis BCG although these may also be inhibiting other enzymes. The ether linked di-triclosan derivative (38) displayed excellent in vitro isolated enzyme inhibition results comparable with triclosan, but at a higher MIC (125 μg mL?1 ). These compounds offer good opportunities as leads for further optimisation.

C(sp3)-H Monoarylation of Methanol Enabled by a Bidentate Auxiliary

With the assistance of a practical directing group (COAQ), the first catalytic protocol for the palladium-catalyzed C(sp3)-H monoarylation of methanol has been developed, offering an invaluable synthesis means to establish extensive derivatives of crucial arylmethanol functional fragments. Furthermore, the gram-scale reaction, broad substrate scope, excellent functional group compatibility, and even the practical synthesis of medicines further demonstrate the usefulness of this strategy.

Catalytic Enantio- And Diastereoselective Cyclopropanation of 2-Azadienes for the Synthesis of Aminocyclopropanes Bearing Quaternary Carbon Stereogenic Centers

We report the catalytic enantio- and diastereoselective preparation of aminocyclopropanes by the cyclopropanation of terminal and (Z)-internal 2-azadienes with donor/acceptor carbenes derived from α-diazoesters. The resulting cyclopropanes bear quaternary carbon stereogenic centers vicinal to the amino-substituted carbon and are formed as a single diastereomer in up to 99:1 er and 97% yield with 0.5 mol % of Rh2(DOSP)4 and only 1.5 equiv of the diazo reagent. Transformations with internal azadienes afford cyclopropanes with three contiguous stereogenic centers.

Diazirine-containing RNA photo-cross-linking probes for capturing microRNA targets

Here, we report the applicability of diazirine-containing RNA photo-cross-linking probes for the identification of microRNA (miRNA) targets. The RNA cross-linking probes were synthesized by substituting the RNA nucleobases with nucleoside analogues such as 1-O-[3-(3-trifluoromethyl-3H- diazirin-3-yl)]benzyl-β-d-ribofuranose or 1-O-[4-(3-trifluoromethyl-3H- diazirin-3-yl)]benzyl-β-d-ribofuranose that carry aryl trifluoromethyl diazirine moieties. The probes were successfully cross-linked with synthetic RNAs containing the four natural nucleosides on the opposite site of the nucleoside analogues. Furthermore, it was found that miRNAs containing these analogues were effective in regulating the expression of their target genes. Thus, RNAs containing the nucleoside analogues are promising candidates as photo-cross-linking probes to identify the target mRNAs of miRNAs.

Synthesis and biological evaluation of optically active Ki16425

An enantionselective synthesis of both enantiomers of Ki16425, which possesses selective LPA antagonistic activity, was achieved. The isoxazole core was constructed by a 1,3-dipolar cycloaddition of nitrile oxide with alkyne and condensation with the optically active α-phenethyl alcohol segment, which was prepared by an enantioselective reduction of arylmethylketone. Biological evaluation of both enantiomers of Ki16425 revealed that the (R)-isomer showed much higher antagonistic activity for LPA1 and LPA3 receptors.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Total synthesis of the cyclopeptide alkaloid abyssenine A. Application of inter- and intramolecular copper-mediated coupling reactions in organic synthesis

(Chemical Equation Presented) The first total synthesis of the 15-membered ring cyclopeptide alkaloid abyssenine A 1 has been achieved with a longest linear sequence of 15 steps. Central to the synthetic approach was an efficient copper-mediated Ullmann c

Design, synthesis, and biological evaluation of potent discodermolide fluorescent and photoaffinity molecular probes

(Chemical Equation Presented) The design, synthesis, and biological evaluation of a series of (+)-discodermolide molecular probes possessing photoaffinity and fluorescent appendages has been achieved. Stereoselective olefin cross-metathesis comprised a ke

Model reactions targeted at the synthesis of carbon-14 labeled CI-996, a potent antagonist of angiotensin II receptor (1)

A reaction sequence suitable for the preparation of an analog of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-4-[2-(tr ifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid, with 14C at the methylene bridge was developed. The would-be labeled fragment (12) was derived from 4-iodobenzenemethanol (6) which itself was constructed from 1,4-dibromobenzene by the application of silicon chemistry. Pd(o) catalyzed coupling of TBDMS protected 6 and a tetrazole borate 10 gave the compound 12 which upon further transformation to the mesylate 13, N-alkylated an imidazole to furnish target compound.